The role of the urologist, BCG vaccine administration, and SARS‐CoV‐2: An overview
Nathan A. Brooks(Eli Lilly (United States)), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Helen Zafirakis(Mater Misericordiae University Hospital), Paul K. Hegarty(Mater Misericordiae University Hospital), Vikram M. Narayan(Emory University), Xiang‐Yang Han(The University of Texas MD Anderson Cancer Center)
Cited by 10
Related Papers
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
What surgical resection margins are required to achieve oncological control in men with primary penile cancer?
|British Journal of Urology|2005|310
Recurrence mechanisms of non-muscle-invasive bladder cancer — a clinical perspective
|Nature Reviews Urology|2022|196
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer
|The Journal of Urology|2019|190